Value for money from HPV vaccination and cervical screening

Hum Vaccin Immunother. 2012 Jun;8(6):828-30. doi: 10.4161/hv.19807. Epub 2012 Jun 1.


Introduction of human papillomavirus (HPV) vaccination programs raises some important questions about the future organization of cervical screening programs. Two studies--from NZ and Canada--have addressed the question of what combination of vaccination and screening strategies might be most cost-effective in preventing cervical cancer. Both studies indicate that some modifications to existing screening programs may be desirable as immunized females enter these programs. Variables in HPV vaccination that are likely to be particularly important for determining the future cost-effectiveness of cervical screening programs include: vaccine uptake rate, compliance with full doses, timely completion of doses, duration of protection, male vaccination and HPV infection rate. If value for money is to be achieved, it is important that the appropriate data are collected so that policy makers can consider the combined impact of these two programs on costs and health outcomes.

MeSH terms

  • Female
  • Humans
  • Mass Screening / economics*
  • Papillomavirus Vaccines / economics*
  • Papillomavirus Vaccines / therapeutic use*
  • Uterine Cervical Neoplasms / diagnosis*
  • Uterine Cervical Neoplasms / immunology
  • Uterine Cervical Neoplasms / prevention & control*
  • Vaccination / economics*


  • Papillomavirus Vaccines